-
1
-
-
79956001465
-
Consensus recommendations for standard investigative workup: report of the International Myeloma Workshop Consensus Panel 3
-
[1] Dimopoulos, M., Kyle, R., Fermand, J.P., et al. Consensus recommendations for standard investigative workup: report of the International Myeloma Workshop Consensus Panel 3. Blood 117:18 (2011), 4701–4705.
-
(2011)
Blood
, vol.117
, Issue.18
, pp. 4701-4705
-
-
Dimopoulos, M.1
Kyle, R.2
Fermand, J.P.3
-
2
-
-
60149096306
-
International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders
-
[2] Dispenzieri, A., Kyle, R., Merlini, G., et al. International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders. Leukemia 23:2 (2009), 215–224.
-
(2009)
Leukemia
, vol.23
, Issue.2
, pp. 215-224
-
-
Dispenzieri, A.1
Kyle, R.2
Merlini, G.3
-
3
-
-
38349136782
-
Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma
-
[3] Dispenzieri, A., Kyle, R.A., Katzmann, J.A., et al. Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma. Blood 111:2 (2008), 785–789.
-
(2008)
Blood
, vol.111
, Issue.2
, pp. 785-789
-
-
Dispenzieri, A.1
Kyle, R.A.2
Katzmann, J.A.3
-
4
-
-
84943583461
-
Utility of serum free light chain measurements in multiple myeloma patients not achieving complete response to therapy
-
[4] Alhaj Moustafa, M., Rajkumar, S.V., Dispenzieri, A., et al. Utility of serum free light chain measurements in multiple myeloma patients not achieving complete response to therapy. Leukemia 29:10 (2015), 2033–2038.
-
(2015)
Leukemia
, vol.29
, Issue.10
, pp. 2033-2038
-
-
Alhaj Moustafa, M.1
Rajkumar, S.V.2
Dispenzieri, A.3
-
5
-
-
58249097191
-
Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma
-
[5] Kyle, R.A., Rajkumar, S.V., Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma. Leukemia 23:1 (2009), 3–9.
-
(2009)
Leukemia
, vol.23
, Issue.1
, pp. 3-9
-
-
Kyle, R.A.1
Rajkumar, S.V.2
-
6
-
-
79955977910
-
Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1
-
[6] Rajkumar, S.V., Harousseau, J.L., Durie, B., et al. Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. Blood 117:18 (2011), 4691–4695.
-
(2011)
Blood
, vol.117
, Issue.18
, pp. 4691-4695
-
-
Rajkumar, S.V.1
Harousseau, J.L.2
Durie, B.3
-
7
-
-
34249696500
-
Detection by immunofixation of M proteins in hypogammaglobulinemic patients with normal serum protein electrophoresis results
-
[7] Lakshminarayanan, R., Li, Y., Janatpour, K., Beckett, L., Jialal, I., Detection by immunofixation of M proteins in hypogammaglobulinemic patients with normal serum protein electrophoresis results. Am. J. Clin. Pathol. 127:5 (2007), 746–751.
-
(2007)
Am. J. Clin. Pathol.
, vol.127
, Issue.5
, pp. 746-751
-
-
Lakshminarayanan, R.1
Li, Y.2
Janatpour, K.3
Beckett, L.4
Jialal, I.5
-
8
-
-
84942437054
-
Monoclonal antibodies in multiple myeloma come of age
-
[8] Raje, N., Longo, D.L., Monoclonal antibodies in multiple myeloma come of age. N. Engl. J. Med. 373:13 (2015), 1264–1266.
-
(2015)
N. Engl. J. Med.
, vol.373
, Issue.13
, pp. 1264-1266
-
-
Raje, N.1
Longo, D.L.2
-
9
-
-
84927177719
-
Current treatment landscape for relapsed and/or refractory multiple myeloma
-
[9] Dimopoulos, M.A., Richardson, P.G., Moreau, P., Anderson, K.C., Current treatment landscape for relapsed and/or refractory multiple myeloma. Nat. Rev. Clin. Oncol. 12:1 (2015), 42–54.
-
(2015)
Nat. Rev. Clin. Oncol.
, vol.12
, Issue.1
, pp. 42-54
-
-
Dimopoulos, M.A.1
Richardson, P.G.2
Moreau, P.3
Anderson, K.C.4
-
10
-
-
84942436321
-
Targeting CD38 with daratumumab monotherapy in multiple myeloma
-
[10] Lokhorst, H.M., Plesner, T., Laubach, J.P., et al. Targeting CD38 with daratumumab monotherapy in multiple myeloma. N. Engl. J. Med. 373:13 (2015), 1207–1219.
-
(2015)
N. Engl. J. Med.
, vol.373
, Issue.13
, pp. 1207-1219
-
-
Lokhorst, H.M.1
Plesner, T.2
Laubach, J.P.3
-
11
-
-
84959423326
-
Clinical efficacy and management of monoclonal antibodies targeting CD38 and SLAMF7 in multiple myeloma
-
[11] van de Donk, N.W., Moreau, P., Plesner, T., et al. Clinical efficacy and management of monoclonal antibodies targeting CD38 and SLAMF7 in multiple myeloma. Blood 127:6 (2016), 681–695.
-
(2016)
Blood
, vol.127
, Issue.6
, pp. 681-695
-
-
van de Donk, N.W.1
Moreau, P.2
Plesner, T.3
-
12
-
-
84953325096
-
Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial
-
[12] Lonial, S., Weiss, B.M., Usmani, S.Z., et al. Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial. Lancet 387:10027 (2016), 1551–1560.
-
(2016)
Lancet
, vol.387
, Issue.10027
, pp. 1551-1560
-
-
Lonial, S.1
Weiss, B.M.2
Usmani, S.Z.3
-
13
-
-
84953234682
-
Daratumumab in multiple myeloma
-
[13] Rajkumar, S.V., Daratumumab in multiple myeloma. Lancet, 2016.
-
(2016)
Lancet
-
-
Rajkumar, S.V.1
-
14
-
-
84969776462
-
Interference of daratumumab in monitoring multiple myeloma patients using serum immunofixation electrophoresis can be abrogated using the daratumumab IFE reflex assay (DIRA)
-
[14] van de Donk, N.W., Otten, H.G., El Haddad, O., et al. Interference of daratumumab in monitoring multiple myeloma patients using serum immunofixation electrophoresis can be abrogated using the daratumumab IFE reflex assay (DIRA). Clin. Chem. Lab. Med., 2016.
-
(2016)
Clin. Chem. Lab. Med.
-
-
van de Donk, N.W.1
Otten, H.G.2
El Haddad, O.3
-
15
-
-
84969835048
-
Monitoring multiple myeloma patients treated with daratumumab: teasing out monoclonal antibody interference
-
[15] McCudden, C., Axel, A.E., Slaets, D., et al. Monitoring multiple myeloma patients treated with daratumumab: teasing out monoclonal antibody interference. Clin. Chem. Lab. Med., 2016.
-
(2016)
Clin. Chem. Lab. Med.
-
-
McCudden, C.1
Axel, A.E.2
Slaets, D.3
|